Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23425065)

1.

Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study.

Hayashi N, George J, Shiroeda H, Saito T, Toshikuni N, Tsuchishima M, Arisawa T, Tsutsumi M.

J Gastroenterol Hepatol. 2013 Jun;28(6):1015-8. doi: 10.1111/jgh.12137.

PMID:
23425065
2.

Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).

Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; ANRS HC16 GAMMATRI Trial Group.

J Gastroenterol Hepatol. 2013 Feb;28(2):329-34. doi: 10.1111/jgh.12060.

PMID:
23190183
3.

Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study.

Nanke Y, Kamatani N, Okamoto T, Ogiuchi H, Kotake S.

Drugs R D. 2008;9(6):455-9. doi: 10.2165/0126839-200809060-00008.

PMID:
18989994
4.

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.

Jiménez-Luévano MÁ, Lerma-Díaz JM, Hernández-Flores G, Jiménez-Partida MÁ, Bravo-Cuellar A.

Ann Hepatol. 2013 Mar-Apr;12(2):248-55.

PMID:
23396736
5.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group.

J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x.

PMID:
22098185
6.

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E.

Hepatology. 2010 Sep;52(3):822-32. doi: 10.1002/hep.23743.

PMID:
20564352
7.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
8.

Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?

Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.

J Ocul Pharmacol Ther. 2013 Apr;29(3):345-8. doi: 10.1089/jop.2012.0169. Epub 2012 Oct 31.

PMID:
23113644
9.

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V.

Cent Eur J Public Health. 2012 Jun;20(2):150-5.

PMID:
22966742
10.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
11.

Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.

Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, Koike K.

J Gastroenterol. 2013 Feb;48(2):254-68. doi: 10.1007/s00535-012-0631-y. Epub 2012 Jul 12.

PMID:
22790350
12.

Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.

Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.

J Viral Hepat. 2009 Mar;16(3):168-77. doi: 10.1111/j.1365-2893.2008.01059.x. Epub 2008 Oct 17.

PMID:
19175874
13.

Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.

Nagao Y, Hashimoto K, Sata M.

BMC Gastroenterol. 2012 Nov 2;12:155. doi: 10.1186/1471-230X-12-155.

14.

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.

Jin YJ, Lee JW, Lee JI, Park SH, Park CK, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Sohn JH, Yang JM, Han S.

BMC Gastroenterol. 2013 Apr 29;13:74. doi: 10.1186/1471-230X-13-74.

15.

Identification of connexins in human oral mucosa and therapeutic effect of irsogladine maleate on aphthous stomatitis.

Hara A, Murata T, Uemura R, Miura T, Fukui K, Matsukawa H, Kasiwagi K, Ito T, Yoshioka M, Hibi T.

J Gastroenterol. 1999 Feb;34(1):1-6.

PMID:
10204603
16.

Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C.

Pavan MH, Pavin EJ, Gonçales Jr FL, Zantut-Wittmann DE.

Braz J Infect Dis. 2011 Sep-Oct;15(5):449-56. Erratum in: Braz J Infect Dis. 2013 Jan-Feb;17(1):122. Wittmann, Denise Engelbrecht Zantut [corrected to Zantut-Wittmann, Denise E].

17.

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.

Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K.

J Hepatol. 2012 May;56(5):1012-8. doi: 10.1016/j.jhep.2011.12.020. Epub 2012 Jan 17.

PMID:
22266603
19.

Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.

Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki N, Mizokami M.

J Gastroenterol Hepatol. 2012 Sep;27(9):1461-6. doi: 10.1111/j.1440-1746.2012.07171.x.

PMID:
22554247
20.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk